Diasorin SpA

DIA: XMIL (ITA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€388.00PvrcwkPsjkgzbfs

DiaSorin Does Not Disappoint in Q3 Despite Dilutive Impact of Luminex; Shares Still Overvalued

Narrow-moat DiaSorin reported another impressive quarter and exceeded our expectations with 50% sales growth and 17% net income growth. We plan to moderately increase our EUR 112 fair value estimate after accounting for ongoing strong results. Because our model includes a weighted average U.S. corporate tax rate of 26%, we would also anticipate an approximate 2.5% increase to our fair value estimate if corporate tax rate increases are excluded from the Build Back Better Act still under negotiation.

Sponsor Center